Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TARS Stock Forecast 2026-2027
$67.72
Current Price
$2.88B
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TARS Price Targets
+55.1%
To High Target of $105.00
+40.3%
To Median Target of $95.00
+29.9%
To Low Target of $88.00
TARS Price Momentum
-6.7%
1 Week Change
-3.0%
1 Month Change
+37.5%
1 Year Change
-17.3%
Year-to-Date Change
-20.6%
From 52W High of $85.25
+75.9%
From 52W Low of $38.51
📊 TOP ANALYST CALLS
Did TARS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Tarsus is one of their latest high-conviction picks.
Latest TARS Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, TARS has a bullish consensus with a median price target of $95.00 (ranging from $88.00 to $105.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $67.72, the median forecast implies a 40.3% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Francois Brisebois at Oppenheimer, projecting a 55.1% upside. Conversely, the most conservative target is provided by Matthew Caufield at HC Wainwright & Co., suggesting a 29.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TARS Analyst Ratings
9
Buy
0
Hold
0
Sell
TARS Price Target Range
Low
$88.00
Average
$95.00
High
$105.00
Current: $67.72
Latest TARS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TARS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 25, 2026 | Guggenheim | Eddie Hickman | Buy | Maintains | $90.00 |
| Feb 25, 2026 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $105.00 |
| Dec 9, 2025 | Barclays | Glen Santangelo | Overweight | Initiates | $100.00 |
| Nov 20, 2025 | Mizuho | Graig Suvannavejh | Outperform | Initiates | $100.00 |
| Nov 5, 2025 | Guggenheim | Eddie Hickman | Buy | Maintains | $87.00 |
| Oct 20, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $88.00 |
| May 27, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Assumes | $72.00 |
| May 5, 2025 | Goldman Sachs | Andrea Tan | Neutral | Maintains | $51.00 |
| May 2, 2025 | Guggenheim | Eddie Hickman | Buy | Maintains | $84.00 |
| Mar 6, 2025 | Jefferies | Anthony Petrone | Buy | Maintains | $58.00 |
| Feb 26, 2025 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $73.00 |
| Feb 26, 2025 | Barclays | Balaji Prasad | Overweight | Maintains | $60.00 |
| Feb 26, 2025 | Guggenheim | Eddie Hickman | Buy | Maintains | $78.00 |
| Feb 24, 2025 | Guggenheim | Eddie Hickman | Buy | Reiterates | $N/A |
| Feb 10, 2025 | Guggenheim | Eddie Hickman | Buy | Reiterates | $N/A |
| Jan 27, 2025 | Barclays | Balaji Prasad | Overweight | Maintains | $62.00 |
| Jan 22, 2025 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $72.00 |
| Nov 15, 2024 | Goldman Sachs | Andrea Tan | Neutral | Maintains | $41.00 |
| Nov 14, 2024 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $65.00 |
| Aug 9, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $63.00 |
Tarsus Pharmaceuticals Inc. (TARS) Competitors
The following stocks are similar to Tarsus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Tarsus Pharmaceuticals Inc. (TARS) Financial Data
Tarsus Pharmaceuticals Inc. has a market capitalization of $2.88B with a P/E ratio of -42.6x. The company generates $451.36M in trailing twelve-month revenue with a -14.7% profit margin.
Revenue growth is +128.4% quarter-over-quarter, while maintaining an operating margin of -5.3% and return on equity of -23.4%.
Valuation Metrics
Market Cap
$2.88B
Enterprise Value
$2.72B
P/E Ratio
-42.6x
PEG Ratio
0.6x
Price/Sales
6.8x
Growth & Margins
Revenue Growth (YoY)
+128.4%
Gross Margin
+92.8%
Operating Margin
-5.3%
Net Margin
-14.7%
EPS Growth
+128.4%
Financial Health
Cash/Price Ratio
+14.5%
Current Ratio
3.9x
Debt/Equity
24.2x
ROE
-23.4%
ROA
-9.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Tarsus Pharmaceuticals Inc. (TARS) Business Model
About Tarsus Pharmaceuticals Inc.
What They Do
Develops therapeutics for ophthalmic conditions.
Business Model
Tarsus Pharmaceuticals generates revenue by developing and commercializing innovative therapeutics aimed at treating unmet medical needs in eye care. The company focuses on diseases affecting the anterior segment of the eye, utilizing advanced diagnostic tools and delivery mechanisms to enhance the efficacy and safety of its treatments.
Additional Information
Headquartered in Irvine, California, Tarsus Pharmaceuticals is actively engaged in collaboration with researchers and clinical experts to advance its product pipeline, which includes a targeted investigational compound for Demodex blepharitis. The company's commitment to improving patient outcomes and supporting healthcare innovation positions it as a key player in the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
370
CEO
Dr. Bobak R. Azamian M.D.
Country
United States
IPO Year
2020
Website
tarsusrx.comTarsus Pharmaceuticals Inc. (TARS) Latest News & Analysis
Latest News
Quick Summary
Tarsus Pharmaceuticals reports increased Xdemvy sales now surpassing SG&A expenses. They've appointed David Pyott to the Board and have upcoming clinical catalysts in H1'27.
Why It Matters
Tarsus Pharmaceuticals shows potential for profitability with Xdemvy sales outpacing expenses, and leadership changes may enhance strategic direction. Upcoming clinical trials could drive future growth.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Tarsus Pharmaceuticals (NASDAQ: TARS) has begun dosing participants in a Phase 2 trial for TP-05, an oral therapy aimed at preventing Lyme disease by targeting infected ticks.
Why It Matters
Tarsus Pharmaceuticals' Phase 2 trial for TP-05 could disrupt Lyme disease prevention, potentially enhancing market position and driving stock value if successful.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
An executive at Tarsus Pharmaceuticals sold 12,274 shares for about $839,000, at an average price of $68.36 per share, with no indirect ownership reported.
Why It Matters
The sale of shares by a Tarsus executive may signal insider sentiment about the company's future, potentially affecting investor confidence and stock prices.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
Tarsus Pharmaceuticals (NASDAQ: TARS) received a $15 million milestone payment after the NMPA approved its ophthalmic solution TP-03 (XDEMVY®) in China.
Why It Matters
Tarsus Pharmaceuticals' regulatory approval for TP-03 in China triggers a $15 million milestone payment, enhancing cash flow and signaling growth potential, positively impacting investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
1 month ago
Quick Summary
Tarsus Pharmaceuticals, Inc. (TARS) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting key developments for investors.
Why It Matters
Tarsus Pharmaceuticals’ presentation at a major healthcare conference could signal new developments or insights, influencing investor sentiment and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Maker Of Eye Drops Has Sights On Buy Point
1 month ago
Quick Summary
An eye drops stock is forming a cup base after a biopharmaceutical earnings report, with Wall Street optimistic about potential profits ahead.
Why It Matters
The stock's cup base formation suggests potential price appreciation, and positive earnings signals increased investor confidence, indicating possible future gains.
Source: Investors Business Daily
Market Sentiment:
Neutral
Frequently Asked Questions About TARS Stock
What is Tarsus Pharmaceuticals Inc.'s (TARS) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Tarsus Pharmaceuticals Inc. (TARS) has a median price target of $95.00. The highest price target is $105.00 and the lowest is $88.00.
Is TARS stock a good investment in 2026?
According to current analyst ratings, TARS has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $67.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TARS stock?
Wall Street analysts predict TARS stock could reach $95.00 in the next 12 months. This represents a 40.3% increase from the current price of $67.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tarsus Pharmaceuticals Inc.'s business model?
Tarsus Pharmaceuticals generates revenue by developing and commercializing innovative therapeutics aimed at treating unmet medical needs in eye care. The company focuses on diseases affecting the anterior segment of the eye, utilizing advanced diagnostic tools and delivery mechanisms to enhance the efficacy and safety of its treatments.
What is the highest forecasted price for TARS Tarsus Pharmaceuticals Inc.?
The highest price target for TARS is $105.00 from Francois Brisebois at Oppenheimer, which represents a 55.1% increase from the current price of $67.72.
What is the lowest forecasted price for TARS Tarsus Pharmaceuticals Inc.?
The lowest price target for TARS is $88.00 from Matthew Caufield at HC Wainwright & Co., which represents a 29.9% increase from the current price of $67.72.
What is the overall TARS consensus from analysts for Tarsus Pharmaceuticals Inc.?
The overall analyst consensus for TARS is bullish. Out of 11 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $95.00.
How accurate are TARS stock price projections?
Stock price projections, including those for Tarsus Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 12:33 PM UTC